Roivant Sciences Ltd.
Stock Forecast, Prediction & Price Target
Roivant Sciences Ltd. (ROIV) stock Price Target by analysts
$17
Potential upside: 42.85%
Roivant Sciences Ltd. price prediction
What is Roivant Sciences Ltd. stock analysts` prediction?
Roivant Sciences Ltd. stock forecast: Based on 1 Wall Street analysts` predicted price targets for Roivant Sciences Ltd. in the last 3 months, the avarage price target is $17, with a high forecast of $NaN. The average price target represents a 42.85% change from the last price of $11.9.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Roivant Sciences Ltd. stock Price Target by analysts
Full breakdown of analysts given Roivant Sciences Ltd. price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
David Risinger Leerink Partners | 0% 0/1 | 11 months ago | $17 42.85% upside | $11.92 | StreetInsider | Previous targets (0) |
Corinne Jenkins Goldman Sachs | 0% 0/3 | about 1 year ago | $17 42.85% upside | $12.06 | StreetInsider | Previous targets (2) |
Chi Fong Bank of America Securities | 0% 0/1 | about 1 year ago | $12.5 5.04% upside | $12.46 | StreetInsider | Previous targets (0) |
Allison Bratzel Piper Sandler | 0% 0/1 | over 1 year ago | $20 68.06% upside | $10.39 | StreetInsider | Previous targets (0) |
Douglas Tsao H.C. Wainwright | 0% 0/1 | over 1 year ago | $18 51.26% upside | $10.92 | StreetInsider | Previous targets (0) |
Neena Bitritto-Garg Deutsche Bank | 0% 0/1 | over 1 year ago | $15 26.05% upside | $10.92 | TheFly | Previous targets (0) |
Corinne Jenkins Goldman Sachs | 0% 0/3 | over 1 year ago | $18 51.26% upside | $10.92 | StreetInsider | Previous targets (2) |
Corinne Jenkins Goldman Sachs | 0% 0/3 | over 1 year ago | $16 34.45% upside | $10.62 | StreetInsider | Previous targets (2) |
Unknown Citigroup | N/A | over 2 years ago | $14 17.64% upside | $7.56 | Benzinga | N/A |
Unknown Leerink Partners | N/A | almost 3 years ago | $10 -15.96% downside | $7.32 | Benzinga | N/A |
Unknown Citigroup | N/A | about 3 years ago | $10 -15.96% downside | $4.04 | Benzinga | N/A |
Unknown Goldman Sachs | N/A | over 3 years ago | $12 0.84% upside | $3.86 | Benzinga | N/A |
Unknown Cantor Fitzgerald | N/A | over 3 years ago | $15 26.05% upside | $4 | Benzinga | N/A |
Roivant Sciences Ltd. Financial Estimates
Roivant Sciences Ltd. Revenue Estimates
Roivant Sciences Ltd. EBITDA Estimates
Roivant Sciences Ltd. Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 3/31/2021 | 3/31/2022 | 3/31/2024 | 3/31/2026 | 3/31/2027 | 3/31/2028 | 3/31/2029 |
Revenue
% change YoY
| $23.79M N/A | $55.28M 132.34% | $124.79M 125.72% | Avg: $258.53M Low: $156.01M High: $412.21M avg. 107.16% | Avg: $646.63M Low: $435.92M High: $964.05M avg. 150.11% | Avg: $1.50B Low: $1.01B High: $2.24B avg. 133.14% | Avg: $2.52B Low: $1.70B High: $3.76B avg. 67.52% |
Net Income
% change YoY
| $-809.23M N/A | $-924.11M -14.19% | $4.34B 570.60% | Avg: $-833.42M Low: $-1.56B High: $-714.70M avg. -119.16% | Avg: $-370.75M Low: $-656.52M High: $-224.38M avg. 55.51% | Avg: $96.40M Low: $55.56M High: $157.91M avg. 126.00% | Avg: $821.07M Low: $473.25M High: $1.34B avg. 751.72% |
EBITDA
% change YoY
| $-895.73M N/A | $-1.49B -67.44% | $4.31B 387.38% | Avg: $-155.12M Low: $-247.32M High: $-93.60M avg. -103.59% | Avg: $-387.98M Low: $-578.43M High: $-261.55M avg. -150.11% | Avg: $-904.56M Low: $-1.34B High: $-609.80M avg. -133.14% | Avg: $-1.51B Low: $-2.25B High: $-1.02B avg. -67.52% |
EPS
% change YoY
| -$1.18 N/A | -$1.38 -16.94% | $5.55 502.17% | Avg: -$1.19 Low: -$1.88 High: -$0.86 avg. -121.41% | Avg: -$0.53 Low: -$0.79 High: -$0.27 avg. 55.62% | Avg: $0.12 Low: $0.07 High: $0.19 avg. 121.99% | Avg: $0.99 Low: $0.57 High: $1.62 avg. 751.72% |
Operating Expenses
% change YoY
| $1.09B N/A | $1.25B 15.14% | $-4.13B -428.50% | Avg: $2.33B Low: $1.41B High: $3.72B avg. 156.56% | Avg: $5.84B Low: $3.94B High: $8.71B avg. 150.11% | Avg: $13.63B Low: $9.18B High: $20.32B avg. 133.14% | Avg: $22.83B Low: $15.39B High: $34.04B avg. 67.52% |
FAQ
What is Roivant Sciences Ltd. stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 203.51% in 2026-2029.
We have gathered data from 5 analysts. Their low estimate is -1.56B, average is -833.42M and high is -714.70M.
What is Roivant Sciences Ltd. stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 114.48% in 2026-2029.
We have gathered data from 8 analysts. Their low revenue estimate is $156.01M, average is $258.53M and high is $412.21M.
What is Roivant Sciences Ltd. stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 201.98% in 2026-2029.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$1.88, average is -$1.19 and high is $-0.86.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Roivant Sciences Ltd. stock. The most successful analyst is David Risinger.